TrialBMC cancer2020

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.

Bastiaan M Privé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.